All In Biotech

NDA 022308 · Bausch and Lomb

Besivance

Besifloxacin Hydrochloride · Ophthalmic · Quinolone Antimicrobial

Novel

Last checked: Nov 20, 2026Latest source record: Apr 3, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 28, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

22

7 Phase 3, 0 recruiting

FAERS reports

969

423 serious, 67 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 28, 2026.

Besifloxacin ophthalmic suspension 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans * CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius * *Efficacy for this organism was studied in fewer than 10 infections. Besifloxacin ophthalmic suspension 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. ( 1 )

Mechanism: Besifloxacin is a fluoroquinolone antibacterial [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BESIVANCE · BESIFLOXACIN HYDROCHLORIDE EQ 0.6% BASE · SUSPENSION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Besifloxacin" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain104
  • vision blurred82
  • eye irritation79
  • off label use78
  • hypersensitivity68
  • ocular hyperaemia60
  • cardiac disorder50
  • chronic kidney disease42
  • drug ineffective36
  • photophobia36
  • impaired healing34
  • foreign body sensation in eyes33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200916
201062
201143
201244
201322
201442
201570
201687
2017106
2018103
201981
202061
202153
202265
202357
202436
202513
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Besivance (Besifloxacin HCl)

2024 spending

$6.8M

Beneficiaries

19,935

30,315 claims

Per beneficiary

$340

$44.02 per unit

View as table
YearSpending
2020$18,027,402
2021$18,032,812
2022$14,250,102
2023$10,644,648
2024$6,786,112

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.